AstraZeneca’s AMPLIFY trial interim analysis demonstrates positive results for Calquence plus venetoclax
James Spargo | July 30, 2024 | News story | Research and Development | AstraZeneca, Haematology, chronic lymphocytic leukaemia, haematology, trial analysis
AstraZeneca has announced positive high-level results from an interim analysis for its AMPLIFY phase 3 trial, combining AstraZeneca’s Calquence (acalabrutinib) with venetoclax, with or without obinutuzumab, in previously untreated adult patients with chronic lymphocytic leukaemia (CLL), compared to standard of care chemotherapy.
The results show a statistically significant and clinically meaningful improvement in the primary endpoint of progression-free survival (PFS). A positive trend was also shown in the secondary endpoint – overall survival (OS) – versus standard of care chemotherapy, however this data is not mature yet.
Jennifer R Brown MD PhD, director of the CLL Center of the Division of Hematologic Malignancies, Dana-Farber Cancer Institute, and the Worthington and Margaret Collette professor of Medicine at Harvard Medical School, and principal investigator of the trial, said: “The AMPLIFY results demonstrate the potential of acalabrutinib and venetoclax with or without obinutuzumab to be effective and well-tolerated fixed-duration treatment options for patients with CLL. This is an important advance in this setting as fixed-duration regimens allow those living with this chronic disease to take breaks from their treatment, thereby decreasing the possibility of long-term adverse events and drug resistance, and improving quality of life.”
Susan Galbraith, executive vice president, Oncology R&D, AstraZeneca, said: “The PFS and OS results from the AMPLIFY phase 3 trial demonstrate the potential of including a Bruton tyrosine kinase (BTK) inhibitor in a fixed-duration regimen and reinforce our leadership in advancing science for patients with CLL. If approved, Calquencewould become the only second-generation BTK inhibitor available as both a treat-to-progression and fixed-duration treatment, providing more options for patients and their healthcare providers.”
James Spargo
Related Content
NICE recommends Benralizumab for Rare Form of Vasculitis
The National Institute for Health and Care Excellence (NICE) has recommended AstraZeneca’s benralizumab (Fasenra) as …
NICE approves AstraZeneca’s dual immunotherapy for advanced liver cancer
AstraZeneca has received a positive recommendation from the National Institute for Health and Care Excellence …
Purpose and people: the enduring power of brand and the evolution of employer identity
Two decades ago, terms like purpose and people were rarely at the forefront of branding …
